相关临床试验
1
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
进行中（未招募）
1
100.0%
暂无批准数据
- The fourth quarter of 2025 witnessed an unprecedented surge in ANDA patent litigation cases, with over 80 new lawsuits filed as generic manufacturers challenged patents protecting major pharmaceutical products. - High-value drug patents faced multiple challenges, including Bayer's Kerendia (finerenone) targeted by at least 10 generic companies and AbbVie's Qulipta (atogepant) facing litigation from multiple manufacturers. - Settlement activity remained robust with over 50 cases resolved, often resulting in injunctions preventing generic entry until patent expiration while allowing FDA approval processes to continue.
- The combination of enzalutamide and radium-223 significantly improved overall survival in men with castration-resistant prostate cancer and bone metastases. - Radiographic progression-free survival was also improved with the combination therapy compared to enzalutamide alone, 19.4 months versus 16.4 months, respectively. - The addition of radium-223 to enzalutamide led to a higher incidence of grade 3 or higher drug-related adverse events, increasing from 19% to 28%. - The PEACE-3 trial suggests this combination as a potential first-line treatment option for metastatic castration-resistant prostate cancer patients with bone metastases.
